Discontinuation of psychotropic medication: a synthesis of evidence across medication classes.
Open accessThe DOI matches its Crossref record; 154 of the 154 references it cites were found in a registry or an index.
Abstract
Pharmacotherapy is an effective treatment modality across psychiatric disorders. Nevertheless, many patients discontinue their medication at some point. Evidence-based guidance for patients, clinicians, and policymakers on rational discontinuation strategies is vital to enable the best, personalized treatment for any given patient. Nonetheless, there is a scarcity of guidelines on discontinuation strategies. In this perspective, we therefore summarize and critically appraise the evidence on discontinuation of six major psychotropic medication classes: antidepressants, antipsychotics, benzodiazepines, mood stabilizers, opioids, and stimulants. For each medication class, a wide range of topics pertaining to each of the following questions are discussed: (1) Who can discontinue (e.g., what are risk factors for relapse?); (2) When to discontinue (e.g., after 1 year or several years of antidepressant use?); and (3) How to discontinue (e.g., what’s the efficacy of dose reduction compared to full cessation and interventions to mitigate relapse risk?). We thus highlight how comparing the evidence across medication classes can identify knowledge gaps, which may pave the way for more integrated research on discontinuation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“although our findings do cast a degree of doubt on the need for routine use of longer-term tapering regimens apart from any theoretical concerns.”
From Incidence and Nature of Antidepressant Discontinuation Symptoms (2025) · cites this paper as [3]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852 · cited 2×
“…for relapse following discontinuation: In bipolar disorder, young age of onset, psychotic features, numerous previous episodes, rapid cycling, comorbid anxiety, comorbid substance use, and persistent subthreshold symptoms are risk factors for recurrence, even during maintenance treatment [76].”
BackgroundSelf-citationPliszka, S. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318054e724 · Cited by 1,765
Faraone, S. V., Banaschewski, T., Coghill, D., Zheng, Y., Biederman, J., Bellgrove, M. A., Newcorn, J. H., Gignac, M., Al Saud, N. M., Manor, I., et al. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.01.022 · Cited by 1,545 · cited 1×
“In clinical practice, tapering stimulants is sometimes considered, while lacking evidence [139, 147].”
BackgroundSelf-citationKennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., Hasnain, M., Jollant, F., Levitt, A. J., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659417 · Cited by 1,181
The Maudsley Prescribing Guidelines in Psychiatry
Taylor, D. M., Barnes, T. R. E., & Young, A. H. (2021) · Wiley eBooks · doi:10.1002/9781119870203 · Cited by 988
Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review
Geddes, J. R., Carney, S. M., Davies, C., Furukawa, T. A., Kupfer, D. J., Frank, E., & Goodwin, G. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12599-8 · Cited by 945
Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Salanti, G., & Davis, J. M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60239-6 · Cited by 931 · cited 2×
“25 % a f t e r 1 y e a r [ 3 ] 3 7 – 70 % [ 47 ] F i r s t e p i s o d e o f p s y c h o s i s ( FE P ) : c o n t i n u e a t l e a s t 1 – 2 y e a r s ( w i t h r a p i d f u ll r e m i ss i o n a n d f e w r i s k f a c t o r s , d i s c o n t i n u a t i o n a f t e r 6 m o n t h s m a y b e c o…”
BackgroundInfluentialCleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759
Research works printed but not linked: 4
- Tripp CC, Rak E, Burker E. A review of effective treatments for patients with co-occurring chronic pain and opioid addiction. VISTAS Online. 2017.
- National Guideline Center. Attention deficit hyperactivity disorder: diagnosis and management. London: National Institute for Health and Care Excellence (NICE); 2019. 29634174
- National Guideline Centre (UK). Withdrawal from pharmacological treatment and drug holidays: attention deficit hyperactivity disorder: diagnosis and management: evidence review I. London: National Institute for Health and Care Excellence (NICE); 2018. 35192265
- World Health Organization. Clinical guidelines for withdrawal management and treatment of drug dependence in closed settings. Geneva: World Health Organization; 2009. 26269862
Cited by
Incidence and Nature of Antidepressant Discontinuation Symptoms
Kalfas, M., Tsapekos, D., Butler, M., McCutcheon, R. A., Pillinger, T., Strawbridge, R., Bhat, B. B., Haddad, P. M., Cowen, P. J., Howes, O. D., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.1362 · Cited by 42
Self-citationFung, C. H., Alessi, C., Martin, J. L., Josephson, K. R., Kierlin, L., Dzierzewski, J. M., Moore, A. A., Badr, M. S., Zeidler, M. R., Kelly, M. R., et al. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2024.5020 · Cited by 28
Costa, B., & Vale, N. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13154398 · Cited by 22
Photodegradation of typical psychotropic drugs in the aquatic environment: a critical review
Wang, C., Guo, R., Guo, C., Yin, H., & Xu, J. F. (2025) · Environmental Science Processes & Impacts · doi:10.1039/d4em00669k · Cited by 13
Montégut, L., Rousseau, A., Ungolo, C., Derosa, L., Fidelle, M., Alves Costa Silva, C., Routy, B., Zitvogel, L., Besse, B., Pasolli, E., et al. (2025) · OncoImmunology · doi:10.1080/2162402x.2025.2528955 · Cited by 8
“44,45 Beyond the epidemiological association between benzodiazepine use and reduced efficacy of immunotherapy, the present study reveals a correlation between benzodiazepine consumption and stigmata of intestinal dysbiosis.”
Wang, Y., Wu, Y., Wang, R., Wang, Z., & Luo, F. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1507639 · Cited by 5
Patient and clinician perspectives on pharmacogenetic testing for antipsychotics
Richards-Brown, M., Wei, Y., Abidoph, R., Varney, L., Cotic, M., Murtough, S., Panconesi, D., Mills, D., Richards‐Belle, A., Khani, N. S., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1689300 · Cited by 5
Panconesi, D., Murtough, S., Cotic, M., Khani, N. S., Varney, L., Richards-Brown, M., Abidoph, R., Mills, D., Richards‐Belle, A., Molai, J., et al. (2026) · The Pharmacogenomics Journal · doi:10.1038/s41397-025-00394-x · Cited by 5
Aekwarangkoon, S., Ward, E. C., Duangsai, S., & Jearawattanakul, S. (2025) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph22111606 · Cited by 3
Tirzepatide vs. semaglutide: clinical decision-making in the GLP-1 landscape
Mondoh, A., Crotty, M., & le Roux, C. W. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2601060 · Cited by 3
Risk of Relapse in Psychotic and Bipolar Disorders After Prenatal Antipsychotic Discontinuation
Liu, X., Smout, S., Mahjani, B., Munk‐Olsen, T., Blæhr, E. E., Robakis, T. K., & Bergink, V. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.0682 · Cited by 3
Environmentally conscious psychopharmacotherapy: Practice recommendations for psychiatrists
Luykx, J. J., Moermond, C., Page, L., Lertxundi, U., & Vinkers, C. H. (2024) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2024.10.003 · Cited by 3
Self-citationPrabahar, K., Ravikumar, A., Jeyabalan, A. P., Ravi, B., Ravikumar, C., PannirukaiSelvan, N., Alqifari, S. F., Sivaraman, V., Shanmugasundaram, N., & Sankar, K. (2025) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2025.174003 · Cited by 2
Supportive Interventions for Deprescribing in Adult Mental Healthcare: A Narrative Review
Tchijevitch, O., Gildberg, F. A., & Birkeland, S. (2025) · Issues in Mental Health Nursing · doi:10.1080/01612840.2025.2562183 · Cited by 2
Mukherjee, S., Skrede, S., & Fernø, J. (2025) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-10009-2 · Cited by 2
Withdrawal effects following treatment discontinuation: A blind spot in evidence-based medicine
Mathioudakis, A. G. (2026) · Med · doi:10.1016/j.medj.2026.101181 · Cited by 2
Louie, K., Jauhar, S., Rubio, J., Brand, B. A., Pillinger, T., Howes, O. D., & McCutcheon, R. A. (2026) · The Lancet Psychiatry · doi:10.1016/s2215-0366(26)00225-7 · Cited by 2
Self-citationBoskovic, D. H., Huang, D., Severtson, S. G., Marci, C. D., Awasthi, S., Ardic, F. C., Eisenberg, D. F., & Kapadia, S. (2026) · Neurology and Therapy · doi:10.1007/s40120-026-01027-6 · Cited by 2
Differential Withdrawal Symptoms of Typical and Atypical Antipsychotics: A Narrative Review
Khaliq, S. A., Tahir, M. U., Sabir, S., & Sheikh, M. (2025) · Journal of Liaquat National Hospital · doi:10.37184/jlnh.2959-1805.3.32 · Cited by 1
Asir, B., Al‐Soleiti, M., & Singh, B. (2026) · Drugs & Aging · doi:10.1007/s40266-026-01315-8 · Cited by 1
Fayedeh, F., Mojahedi, M., & Gharaie, D. (2026) · Journal of Medical Case Reports · doi:10.1186/s13256-026-06384-2 · Cited by 1
Fargier, P.-B., Horowitz, M. A., CHARLES, R., Rousselon, V., Fakra, É., Beyens, M., & Laroche, M. (2026) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.70278 · Cited by 1
The neuropsychopharmacology of treatment discontinuation
Kim, B. S. (2026) · Neuropsychopharmacology · doi:10.1038/s41386-026-02518-8 · Cited by 1
A conceptual framework for addressing treatment withdrawal effects across the evidence pathway
Mathioudakis, A. G., Clarke, M. J., Vestbo, J., & Kontopantelis, E. (2026) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2026.112467 · Cited by 1
Severtson, S. G., Boskovic, D. H., Marci, C. D., Eisenberg, D. F., Abdrabboh, A., & Ardic, F. C. (2026) · Neurology and Therapy · doi:10.1007/s40120-026-01029-4 · Cited by 1
Patient satisfaction with prescription opioid education in primary care
Davies, L. E. M., van den Ham, H. A., Schellekens, A., Philbert, D., & Bouvy, M. L. (2024) · Patient Education and Counseling · doi:10.1016/j.pec.2024.108572 · Cited by 1
Self-citationMultisystem Symptom Burden and Functional Impairment in a Specialty Benzodiazepine Taper CohortPreprint
Madhava, V. S. (2025) · medRxiv · doi:10.1101/2025.10.07.25336923 · Cited by 1
He, B., Mao, Y., Hong, C., & Geng, Y. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.24.707855 · Cited by 1
Khan, Z., McCarthy, C., Dalton, K., Jungo, K. T., Doherty, A. S., Reeve, E., & Moriarty, F. (2026) · medRxiv · doi:10.64898/2026.08.29.26361707 · Cited by 1
Omitting study limitations might have implications for the patients
de Boissieu, P., & Chevret, S. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00566-7
[Discontinuation of psychotropic medication: a critical review of the evidence].
Haaren, P. C. F. V., van Gaalen, J. M., Kupka, R., Penninx, B. W. J. H., Ruhé, H. G., Schellekens, A., Veldman, S. E., Veling, W., Vis, R., Wit, L. E. D., et al. (2024) · PubMed
Self-citationFailure to reintroduce home medication in critically ill patients
Polderman, F. N., Derijks, H. J., Sikma, M. A., & van Marum, R. J. (2025) · Journal of Critical Care · doi:10.1016/j.jcrc.2025.155051
Management of Patient with Neuroleptic Malignant Syndrome
Ginarsyah, R., & Anggraeni, N. R. (2025) · Jurnal Sehat Indonesia (JUSINDO) · doi:10.59141/.v7i2.290
Werawattanachai, C., Hadee, P., Sornsoongneon, J., & Boonlue, T. (2025) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.1177/0976500x251390085
Carter, E., Reed, J., Thompson, M. J., Bennett, L., & Collins, S. (2021) · Specialty journal of Pharmacognosy Phytochemistry and Biotechnology · doi:10.51847/ghks5w75ll
Stollárová, N., Ryan, C. A., Sheaf, G., Keating, D., O’Donoghue, B., & Cadogan, C. A. (2026) · HRB Open Research · doi:10.12688/hrbopenres.14314.1
Strawn, J. R., & Stahl, S. M. (2026) · Cambridge University Press eBooks · doi:10.1017/9781009642187.060
Strawn, J. R., & Stahl, S. M. (2026) · Cambridge University Press eBooks · doi:10.1017/9781009642187.056
Strawn, J. R., & Stahl, S. M. (2026) · Cambridge University Press eBooks · doi:10.1017/9781009642187.048
Strawn, J. R., & Stahl, S. M. (2026) · Cambridge University Press eBooks · doi:10.1017/9781009642187.015
Strawn, J. R., & Stahl, S. M. (2026) · Cambridge University Press eBooks · doi:10.1017/9781009642187.014
Strawn, J. R., & Stahl, S. M. (2026) · Cambridge University Press eBooks · doi:10.1017/9781009642187.031
Strawn, J. R., & Stahl, S. M. (2026) · Cambridge University Press eBooks · doi:10.1017/9781009642187.020
Strawn, J. R., & Stahl, S. M. (2026) · Cambridge University Press eBooks · doi:10.1017/9781009642187.027
Strawn, J. R., & Stahl, S. M. (2026) · Cambridge University Press eBooks · doi:10.1017/9781009642187.003
Strawn, J. R., & Stahl, S. M. (2026) · Cambridge University Press eBooks · doi:10.1017/9781009642187.036
Strawn, J. R., & Stahl, S. M. (2026) · Cambridge University Press eBooks · doi:10.1017/9781009642187.021
Strawn, J. R., & Stahl, S. M. (2026) · Cambridge University Press eBooks · doi:10.1017/9781009642187.046
Strawn, J. R., & Stahl, S. M. (2026) · Cambridge University Press eBooks · doi:10.1017/9781009642187.062
Strawn, J. R., & Stahl, S. M. (2026) · Cambridge University Press eBooks · doi:10.1017/9781009642187.059
Peng, J., Huang, J. T., Hu, C., Zhu, S., Huang, H., Liao, H., Zheng, Q., Yang, B., & Liu, Q. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1806489
Patient experiences with tapering of mood stabilizers in self-reported bipolar spectrum disorder
Woerdman, N., van der Meer, P. B., Brenninkmeijer, J., Vieta, E., van Os, J., Regeer, E. J., & Dols, A. (2026) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2026.101087
Self-citationBrandt, J., Lamberson, N., Bressi, J., Ritvo, A. D., Curle, J., Witt-Doerring, J., DeWert, M., Wright, S., & Horowitz, M. A. (2026) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253261457547
Recommendations on switching or deprescribing hypnotic medications for insomnia
Hajak, G., Fietze, I., Schöbel, C., Saletu, M., Högl, B., & Winter, Y. (2026) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2026.0141
Wolter, D. K., & Mühlig, S. (2025) · Elsevier eBooks · doi:10.1016/b978-3-437-21155-3.00019-8
Pharmacogenetics and Pharmacogenomics in Psychiatry: Challenges and Opportunities
(2026) · Frontiers research topics · doi:10.3389/978-2-8325-8475-0
Zhai, Q., Yan, F., Qi, H., Zhang, L., Wang, G., & Feng, L. (2026) · Psychiatry Research · doi:10.1016/j.psychres.2026.117461
Treatment Adherence and Health Care Utilization After a First Episode of Psychosis
Chi, E., Sridhar, S., Montesano, V. L., Ramos, J., Breitborde, N. J. K., & Seiber, E. E. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.35805
Evidence on drug withdrawal reactions after medication discontinuation: An umbrella reviewPreprint
Khan, Z., Jungo, K. T., Beatty, J., Cullen, P., Spinewine, A., Reeve, E., & Moriarty, F. (2026) · Research Square · doi:10.21203/rs.3.rs-11293956/v1
Rodrigues, G. A., Costa, L., Ribeiro, S. D. S., & Caixeta, M. E. (2026) · International Journal of Medical Science and Clinical Research Studies · doi:10.47191/ijmscrs/v6-i10-14
Monteiro, F. L. F., & da Silva, A. J. D. S. (2026) · RECIMA21 - Revista Científica Multidisciplinar · doi:10.47820/recima21.v7i11.9331
Kim, J., Lee, J., Kim, Y., Joo, S. W., & Yang, B. R. (2026) · CNS Drugs · doi:10.1007/s40263-026-01342-4
Metadata
- Authors
- Vinkers, C. H., Kupka, R. W., Penninx, B. W., Ruhé, H. G., van Gaalen, J. M., van Haaren, P. C. F., Schellekens, A. F. A., Jauhar, S., Ramos-Quiroga, J. A., Vieta, E., Tiihonen, J., Veldman, S. E., Veling, W., Vis, R., de Wit, L. E., & Luykx, J. J.
- Affiliations
- Amsterdam Neuroscience (NL)
- Radboud University Nijmegen (NL)
- King's College London (GB)
- Centro de Investigación Biomédica en Red de Salud Mental (ES)
- University of Helsinki (FI)
- University Medical Center Groningen (NL)
- St. Antonius Ziekenhuis (NL)
- Maastricht University Medical Centre (NL)
- Corresponding author
- Vinkers, Christiaan H.
- ORCID
- Venue
- Molecular Psychiatry
- Published
- 2024-03-19
- Volume
- 29
- Issue
- 8
- Pages
- 2575-2586
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- PMC
- PMC11412909
- OpenAlex
- W4392956861
- Cited by
- 51
- References
- 154
- Citations by year
- 2026: 32 · 2025: 13 · 2024: 5
- FWCI
- 3.13
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Molecular Psychiatry (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, cc-by)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion, other-oa)
- Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by)
- Radboud Repository (Radboud University) (submittedVersion)
- Työväentutkimus Vuosikirja (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by)
- Funders
- Eli Lilly and Company
- Sanofi
- Biogen
- Sunovion
- Wellcome Trust
- ZonMw
- Dainippon Sumitomo Pharma
- Gedeon Richter
- Shionogi
- Hersenstichting
- H. Lundbeck A/S
- Idorsia Pharmaceuticals
- HLS Therapeutics
- Cilag
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- antidepressants, antipsychotic drugs, benzodiazepines, mood stabilizers, opioids, stimulants, relapse risk, dose reduction, tapering, treatment duration, psychopharmacological treatment
- MeSH terms
- Antidepressive Agents, Mental Disorders, Benzodiazepines, Humans, Psychotropic Drugs, Recurrence, Antipsychotic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.